NCT07713212

Brief Summary

To assess whether adding fractional laser to topical corticosteroid improves treatment outcomes in palmoplanter psoriasis compared to topical corticosteroid alone.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at below P25 for phase_4

Timeline
6mo left

Started Aug 2026

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 7, 2026

Completed
13 days until next milestone

First Posted

Study publicly available on registry

July 20, 2026

Completed
26 days until next milestone

Study Start

First participant enrolled

August 15, 2026

Expected
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2027

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2027

Last Updated

July 20, 2026

Status Verified

July 1, 2026

Enrollment Period

6 months

First QC Date

July 7, 2026

Last Update Submit

July 14, 2026

Conditions

Psoriasis

Keywords

psoriasisfractional CO2 lasertopical treatment

Outcome Measures

Primary Outcomes (1)

  • Improvement in Palmoplantar Psoriasis Severity Index (ppPASI) by topical corticosteroids only vs fractional CO₂ laser-assisted delivery of topical corticosteroids

    The primary outcome will be the change in the Palmoplantar Psoriasis Severity Index (ppPASI) score from baseline to the end of treatment (at Week 12). The ppPASI assesses disease severity based on erythema, scaling, and induration/infiltration of the palms and soles, in addition to the affected surface area. Scores range from 0 to 72, with higher scores indicating more severe disease. Treatment success: Achievement of ppPASI-50, ppPASI-75, and ppPASI-90 (≥50%, ≥75%, and ≥90% reduction from baseline).

    3 month

Secondary Outcomes (1)

  • Physician Global Assessment (PGA)

    3 months

Study Arms (2)

fractional carbon dioxide (CO₂) laser-assisted delivery of topical corticosteroids

EXPERIMENTAL

fractional carbon dioxide (CO₂) laser-assisted delivery of topical corticosteroids will be done on palmoplantar psoriasis every 4 weeks

Device: Fractional CO2 laser assisted drug delivery

Topical corticosteroids alone

ACTIVE COMPARATOR

Application of topical corticosteroid alone in patients with palmoplantar psoriasis daily.

Drug: Topical Corticosteroid (TCS)

Interventions

Topical Corticosteroid (TCS)DRUG

Daily application of topical corticosteroids on palmoplantar psoriasis

Also known as: Topical steroids
Topical corticosteroids alone
Fractional CO2 laser assisted drug deliveryDEVICE

Sessions of fractional CO2 every 4 weeks with application of topical steroids

Also known as: fractional CO2 laser
fractional carbon dioxide (CO₂) laser-assisted delivery of topical corticosteroids

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Adults aged ≥18 years
  • Stable psoriasis
  • Confirmed cases of palmoplantar psoriasis (with or without psoriasis elsewhere) dermoscopically(Hand \_held dermoscopy) and histopathologically if required.
  • Willingness to comply with treatment and follow-up
  • Written informed consent obtained

You may not qualify if:

  • Other palmoplantar dermatoses (eczema, tinea, keratoderma)
  • Generlized Pustular psoriasis
  • Erythrodermic psoriasis
  • Use of:
  • Systemic antipsoriatic therapy within 3 months
  • Biologic therapy within 12 weeks
  • Topical treatment on palms/soles within 2 weeks
  • Pregnancy or lactation
  • History of photosensitivity disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cairo University

Cairo, Cairo Governorate, 11562, Egypt

Location

MeSH Terms

Conditions

Psoriasis

Interventions

Adrenal Cortex HormonesSteroids

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

HormonesHormones, Hormone Substitutes, and Hormone AntagonistsFused-Ring CompoundsPolycyclic Compounds

Central Study Contacts

Amira M Elbendary, MD

CONTACT

+201555668584aelbendary@kasralainy.edu.eg

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

July 7, 2026

First Posted

July 20, 2026

Study Start (Estimated)

August 15, 2026

Primary Completion (Estimated)

February 15, 2027

Study Completion (Estimated)

February 15, 2027

Last Updated

July 20, 2026

Record last verified: 2026-07

Locations

EG(1)